The ClearPath Oncology Team

You are here: ClearPath Development Company » The ClearPath Oncology Team

Eric Rowinsky

Eric Rowinsky, MD

Over 25 years of experience in cancer research and responsible for clinical development and registration of several breakthrough oncology agents such as Erbitux ($1.5B in sales), the taxanes for ovary, breast, and other malignancies, Hycamptin® for ovarian cancer

  • EVP and Chief Medical Officer at ImClone (sold to Lilly for $6.5B in 2008); EVP/CMO of Stemline Therapeutics
  • Senior clinical investigator at Johns Hopkins. Designed/led trials for several agents, including Camptosar® and Taxotere®
  • Senior clinical investigator at University of Texas, San Antonio. Led and initial and/or pivotal development studies for Tarceva®, Vectibix®, Iressa®, and Torisel®
  • An Editor-in-Chief of Investigational New Drugs, and an Associate Editor of Cancer Research, Clinical Cancer Research, Annals of Oncology
  • Member of the NCI Board of Scientific Counselors and has published over 230 papers
  • Executive Chairman of RGenix, Inc., and director of publicly traded Biogen Inc., Navidea, and Fortress Biotech




Chuck Finn, PhD

More than 30 years of product development and regulatory experience covering a wide range of product types and therapeutic indications. Experience includes FDA – CBER, biopharma and CRO industry

  • RRD International, Co-Founder, Chairman and CEO, oversees RRD’s development partnerships, managed development teams in Symphony Capital partnership; established ClearPath vaccine development partnership with Astellas Pharma
  • Quintiles, SVP/head of therapeutic business units comprising infectious diseases/immunology/allergy/respiratory/ dermatology, and medical device business units for the US
  • Genetics Institute, Director of Regulatory Affairs, responsible for several clinical stage regulatory programs
  • Miles/Bayer, Associate Director of Regulatory Affairs, responsible for anti-infective regulatory programs
  • Praxis Biologics/Lederle, Sr. Scientist, Director Regulatory Affairs, Praxis developed first Haemophilus b conjugate vaccine for infants (acquired by Lederle for $238M)
  • Staff Fellow, FDA, CBER, Division of Bacterial Products (Vaccines)




Neil Sandler, MBA

Over 30 years of investment and finance experience including > $1B in biopharma development

  • Symphony Capital co-founder and Partner
  • Behrman Capital, Partner. Head of Healthcare
  • Robertson Stephens, Partner, Head of Healthcare
  • PaineWebber Development Corp., Managing Director; Director of product development investments including those with approved products for Amgen, Sanofi/Genzyme, and J&J/Centocor
  • Managed over 125 financings and M&A’s exceeding $13B



Masaki Doi, PhD

Masaki Doi, PhD

30 years experience as a senior executive in the global pharmaceutical industry including venture capital and corporate development

  • At Astellas, as head of Corporate Development, involved in over 20 licensing and 5 M&A transactions including those with biotechnology companies such as Medivation, OSI, Agensys, Seattle Genetics, Regeneron, Fibrogen, Tularik, Protein Design Labs, Genetics Institute and with pharma such as Astra-Zeneca and G.D. Searle (now Pfizer). Responsible for licensing Xtandi (2015 Sales of $1.87B)
  • Founded and managed Yamanouchi Venture Capital (now Astellas Venture Management) in Palo Alto



TarrantScott Tarrant

25 years business development, marketing, sales and corporate strategy in the Life Science Industry; President of RRD International, Board Member at Accium Biosciences and Carepeutics, Inc; former EVP at Xceleron, VP TherImmune Research/Gene Logic